How effective is pitobrutinib?

Pirtobrutinib, also known as Jaypirca, is a novel kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two systemic therapies, including a BTK inhibitor. This drug has attracted widespread attention in the medical community for its unique efficacy and safety.

In a pivotal study, pitobrutinib demonstrated impressive anti-tumor activity. The study is targeting patients with MCL whose cancer has returned or failed to respond to previous treatments, including BTK inhibitors. Research results show that pitobrutinib can significantly reduce the number of cancers in patients and even eliminate all signs of cancer in some patients.

Specifically, the study included164 patients with MCL, 90 of whom had previously received BTK inhibitor treatment and whose condition could be assessed by scan. After treatment with pitobrutinib, about 57% of patients (51 out of 90) showed a complete or partial response, meaning either no cancer remained in their body or the amount of cancer was significantly reduced after treatment. Even more exciting is that about 19% of patients (17 out of 90) achieved a complete response, which means there is no sign of cancer in the body. In addition, the average duration of treatment response reached 18 months, demonstrating the durability of pitobrutinib's efficacy.

Pittobrutinib is a non-covalent (reversible) BTK inhibitor. Its unique mechanism of action gives it significant advantages in reducing side effects and improving safety. Pitobrutinib is associated with a lower risk of cardiotoxicity than traditional covalent BTK inhibitors, making it a relatively safer treatment option.

In general, Pitobrutinib (Jaypirca), with its significant efficacy and good safety profile, provides a new treatment option for lymphoma patients who are ineffective or poorly tolerated by traditional treatments. With the continuous deepening of scientific research and the advancement of technology, it is believed that pitobrutinib will play an even more important role in the field of lymphoma treatment in the future.

xa0

Reference: https://www.ema.europa.eu/en/medicines/human/EPAR/jaypirca